App-Quantinova.ai

MECP2 PROMOTES CISPLATIN-INDUCED ACUTE KIDNEY INJURY THROUGH EPIGENETIC REGULATION OF IRF8

H. Tang - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Acute renal failure

Cisplatin

NUMB PROMOTES AUTOPHAGOSOME MATURATION IN AKI THROUGH DDB1-CUL4 COMPLEX

L. Hao - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cisplatin

A PROTECTOR IN CISPLATIN-INDUCED ACUTE KIDNEY INJURY

Z. Sun - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Acute renal failure

Cisplatin

miR-155 Deficiency Protects Renal Tubular Epithelial Cells From Telomeres And Genomic DNA Damage In Cisplatin-Induced Acute Kidney Injury

Q. Yin - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Acute renal failure

Cisplatin

RacGAP1 ameliorates acute kidney injury by promoting proliferation and suppressing apoptosis of renal tubular cells

W. Zhou - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Ischemia-reperfusion injury

Cisplatin

Safety and feasibility of an HPV therapeutic vaccine (TA-CIN) in patients with HPV16 associated cervical cancer

Stephanie Gaillard - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

Cisplatin

Long Term Survival of GOG 252 ‘Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/GOG Study’

Joan Walker - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ovarian cancer

Cisplatin

Systemic immune checkpoint blockade and intraperitoneal chemo-immunotherapy in recurrent ovarian cancer: An interim analysis

Mackenzy Radolec - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Gynaecological cancer

Cisplatin

Anlotinib plus chemoradiotherapy in the treatment for FIGO stage IB3 and IIB-IVA cervical cancer: A prospective single-arm, single-center, exploratory phase II trial

Shaoxing Sun - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

Cisplatin

Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Bradley Monk - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

Cisplatin

ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed high-risk endometrial cancer

Brian Slomovitz - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

Cisplatin

Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in conservative treatment of malignant ovarian germ cell tumor: a multicenter and retrospective study

Kun Song - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

Cisplatin

Unilateral Upper Extremity Thrombosis with Typical Chest Pain as the First Presentation of Metastatic Necrotic Thymoma

C. H. Vyas - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Autoimmune hemolytic anemia

Cisplatin

An Unusual Case of Squamous Cell Carcinoma Presenting After a 20 Year History of Pulmonary Tuberculosis Treatment

B. Haile - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma

Cisplatin

Endoscopic Ultrasound Videos of Intratumoral Injections Can Inform Initial Drug Dynamics

V. Mori - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cisplatin

Air in the Neck

E. J. Pacheco - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Coronary Artery Disease

Cisplatin

The Impact of Fibrotic Extracellular Matrix on Patient-Derived Lung Tumor Organoids

A. L. Van Der Velden - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Annalisa Chiappella - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Cisplatin

TP53 Null AML Line Does Not Selectively Expand Under Lenalidomide Treatment

Kimberly B. Johansson - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

Cisplatin

Genome-Wide CRISPR Screen Reveals Dependency of PPM1D-mutant Cells on DNA Repair

Linda Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Myeloid neoplasms

Cisplatin

Filters

3952 Abstracts